Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven (NYSE:BHVN)
Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its potential to preserve muscle mass, boost metabolism, and induce weight loss.